Contineum Therapeutics, Inc. — Form 10-Q
Filed November 3, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 2/100
What the filing says
Carmine Stengone (CEO) and Peter Slover (CFO) signed standard Sarbanes-Oxley Section 302 and 906 certifications for the Form 10-Q period ended September 30, 2026, filed November 3, 2026. The certifications attest that financial statements fairly present the company's condition and results, and that disclosure controls and internal controls over financial reporting are effective. No material deficiencies or fraud were disclosed.
Why this rating
Routine quarterly SOX compliance certification; boilerplate disclosure with no substance changes, transactions, or control issues disclosed.
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.